MOONLAKE IMMUNOTHERAPEUTICS

Discover how MoonLake Immunotherapeutics is pioneering a novel nanobody, Sonelokimab, to target inflammation, boosting global patient outcomes and shaping biopharma’s future.

MoonLake’s Phase 3 VELA trials show Sonelokimab achieves sustained 62% HiSCR‑75 in moderate‑to‑severe hidradenitis suppurativa, promising broader IL‑17A/F therapy and potential FDA approval.

MoonLake Immunotherapeutics rallies after analyst upgrades and FDA clarity on its Nanobody drug, Sonelokimab, promising a potential 145% upside for investors.

MoonLake Immunotherapeutics reports >80% ASAS40 response in Phase‑2 axSpA study, driving shares above $20 and boosting confidence in its Sonelokimab pipeline and 2025 financial outlook.

MoonLake Immunotherapeutics faces financial volatility and a class‑action lawsuit amid its pursuit of the Sonelokimab nanobody, highlighting investor risk and biotech innovation.

MoonLake Immunotherapeutics explores the future of inflammatory disease treatment with its investigational Sonelokimab nanobody, navigating market volatility while aiming for clinical success.

MoonLake Immunotherapeutics faces a flood of securities‑fraud lawsuits, investor warnings, and a sharp stock drop, threatening its future and investor confidence.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, is at the center of attention in the healthcare sector due to its innovative treatment, Sonelokimab, and rumors of a potential $3 billion takeover by pharmaceutical giants.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, has seen a surge in interest and stock price following rumors of potential takeover talks with Merck and the success of its investigational treatment, Sonelokimab.

MoonLake Immunotherapeutics’ stock has surged 23% on rumors of a potential $3 billion takeover by Merck, a global pharmaceutical giant.